Pet DNA Tests — What Happens When Science Becomes Saleable Uncertainty
Pet DNA tests arrive with the certainty of a lab report and the actionability of a fortune cookie. A cat's saliva goes into one company's database and comes back flagged for a kidney condition. Sent to another provider, the same sample shows no markers at all. The tests are selling something that looks like medical insight — breed composition, disease risk, ancestry — but they are structured around a choice that gets made before the science even runs: how much uncertainty can be repackaged as useful information before someone objects.
This is not a new problem. When the FDA began scrutinizing 23andMe in 2013, it found that the company was making health claims about genetic markers that the scientific community had not yet validated. The company was not lying about what the DNA showed. It was interpreting those results as if the meaning were settled when it was not. The distinction matters because genetic science moves slowly and interpretations change. A marker associated with Alzheimer's risk in 2010 might show no association by 2015, or show it only in specific populations, or require environmental context nobody had measured. 23andMe eventually separated its ancestry reports (entertainment, essentially harmless) from its health claims (medicine, requiring actual oversight). The company agreed to stop marketing the health interpretations to consumers directly.
Pet genetic testing exists in the gap that opened when 23andMe retreated. The FDA does not regulate pet DNA tests as medical devices because they are sold to animals, not people. The companies are not making explicit disease diagnoses the way a veterinarian would. They are offering risk profiles, breed breakdowns, ancestry maps. Reports that look clinical without being subject to the scrutiny that would make them reliable. A vet cannot use them to diagnose or treat anything. A pet owner cannot know whether the results mean their dog actually carries a marker for hip dysplasia or whether the company has simply flagged a genetic variant that correlates with the condition in some breeds, under some circumstances, in some studies.
The gap between what can be measured and what can be acted on is where genetic testing companies have learned to live. They profit not by solving the ambiguity but by monetizing it. Selling the feeling of understanding your pet's biology without delivering understanding itself. This works because pet owners, like people, want clarity about risk. They want to know what they are paying for. The DNA industry learned a decade ago that what people will actually pay for is the appearance of knowledge in a format that looks authoritative enough to stop questioning. Pet DNA tests are the proof that the lesson held.
When you cannot control whether your interpretation of genetic data is correct, you control what gets measured and how the results get framed. The choice of what to report, what to emphasize, what to flag as significant. That is where the real decision lives. Every company makes it differently because there is no standard that forces them not to. A person building a medical practice, a policy, a decision about their own life, learns to live with uncertainty by testing it against reality. These companies have discovered they can monetize uncertainty itself and never test it at all.
